ArticlePediatric transplantation2025
Pre-Transplant Immunophenotyping in Pediatric Heart Transplant: A Role for the Immunologist?
Article in Pediatric transplantation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundPediatric heart transplant recipients are at risk for complications from prolonged exposure to immunosuppressive drugs, possibly worsened due to over-immune suppression in patients with pre-existing immune abnormalities.
methodsThis was a retrospective, single-center pediatric cohort study and review of baseline immune evaluation in patients referred for heart transplant. Referrals included were from January 1, 2021, to June 31, 2022.
resultsFifty-one patients were referred during the time period with a median age of 5 years (ranging 1 month-20 years). Twenty-seven total patients were transplanted. Given a lack of standardized immune evaluation, results were focused on lymphocyte quantitation, functional testing when available, and T-cell subsets. Outcome measures focused on the number of infections and episodes of rejection requiring treatment. In total, 44.4% of patients experienced rejection, and the mean number of infections in the first 12 months post-heart transplant was 2.1 (range 0-7 total infections).
conclusionsBaseline immune evaluation showed general T and B cell lymphopenia, without a clear connection between outcome differences for the number of infections or episodes of rejection requiring treatment. This small study demonstrated some differences in immune function in patients prior to heart transplant but was inadequately powered to draw conclusions about the effects of immunosuppression on post-transplant outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.